4-(2-氰乙酰基)苯腈 | 71292-11-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(2-氰乙酰基)苯腈
• 中文别名: 4-(2-氰乙酰基）苯腈；(4-氰基苯甲酰基)乙腈
• 英文名称: 4-(2-cyanoacetyl)benzonitrile
• CAS: 71292-11-0
• 化学式: C₁₀H₆N₂O
• mdl: MFCD07021383
• 分子量: 170.17
• InChiKey: HFABIHFBLNTOOW-UHFFFAOYSA-N

物化性质

• 熔点：
  126-129℃
• 沸点：
  408.1±30.0 °C(Predicted)
• 密度：
  1.21

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  4-(2-氰乙酰基)苯腈 在 hydrazine hydrate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II

  摘要：

  In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones were designed, synthesized and evaluated for their TP inhibitory potential. All the synthesized analogues conferred a varying degree of TP inhibitory activity, comparable or better than positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 mu M). A systematic approach to the lead optimization identified compounds 3c and 4a as the most promising TP inhibitors, exhibiting mixed mode of enzyme inhibition. Moreover, selected compounds demonstrated the ability to attenuate the expression of the angiogenic markers (viz. MMP-9 and VEGF) in MDA-MB-231 cells at sublethal concentrations. In addition, molecular docking studies revealed the plausible binding orientation of these inhibitors towards TP, which was in accordance with the experimental results. Taken as a whole, these compounds would constitute a new direction for the design of novel TP inhibitors with promising antiangiogenic properties. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.063
• 作为产物：
  描述：

  对氰基苯甲酸甲酯 以35%的产率得到
  参考文献：
  名称：

  RIDGE D. N.; HANIFIN J. W.; HARTEN L. A.; JOHNSON B. D.; MENSCHIK J.; NIC+, J. MED. CHEM., 1979, 22, NO 11, 1385-1389

  摘要：

  DOI：

文献信息

• Transfer Hydrogenation in Water: Enantioselective, Catalytic Reduction of α-Cyano and α-Nitro Substituted Acetophenones
  作者：Omid Soltani、Martin A. Ariger、Henar Vázquez-Villa、Erick M. Carreira

  DOI：10.1021/ol1008894

  日期：2010.7.2

  Catalytic reduction of α-substituted acetophenones under conditions involving asymmetric transfer hydrogenation in water is described. The reaction is conducted in water and open to air, and formic acid is used as reductant.

  描述了在涉及水中不对称转移氢化的条件下催化还原α-取代的苯乙酮。该反应在水中进行并且对空气开放，并且甲酸用作还原剂。
• Palladium-Catalyzed Carbonylative α-Arylation of <i>tert</i>-Butyl Cyanoacetate with (Hetero)aryl Bromides
  作者：Mikkel T. Jensen、Martin Juhl、Dennis U. Nielsen、Mikkel F. Jacobsen、Anders T. Lindhardt、Troels Skrydstrup

  DOI：10.1021/acs.joc.5b02897

  日期：2016.2.19

  A three-component coupling protocol has been developed for the generation of 3-oxo-3-(hetero)arylpropanenitriles via a carbonylative palladium-catalyzed α-arylation of tert-butyl 2-cyanoacetates with (hetero)aryl bromides followed by an acid-mediated decarboxylation step. Through the combination of only a stoichiometric loading of carbon monoxide and mild basic reaction conditions such as MgCl2 and

  已开发出一种三组分偶联方案，用于通过羰基钯催化的2-氰基乙酸叔丁酯与（杂）芳基溴化物的羰基钯催化的α-芳基化反应，生成3-氧代-3-（杂）芳基丙腈。介导的脱羧步骤。通过仅化学计量的一氧化碳负载量和适度的碱性反应条件（例如MgCl 2和二环己基甲胺）用于去质子化步骤，可以确保该方法具有出色的官能团耐受性。通过使用13 COgen生成的13 C标记的一氧化碳，相应的13获得了C-同位素标记的β-乙腈，这些产物随后可以通过位点特异性13 C-同位素标记转化为氰基炔烃和3-氰基苯并呋喃。
• Synthesis and Structure–Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridines
  作者：Scott Eagon、Jared T. Hammill、Martina Sigal、Kevin J. Ahn、Julia E. Tryhorn、Grant Koch、Briana Belanger、Cory A. Chaplan、Lauren Loop、Anna S. Kashtanova、Kenya Yniguez、Horacio Lazaro、Steven P. Wilkinson、Amy L. Rice、Mofolusho O. Falade、Rei Takahashi、Katie Kim、Ashley Cheung、Celine DiBernardo、Joshua J. Kimball、Elizabeth A. Winzeler、Korina Eribez、Nimisha Mittal、Francisco-Javier Gamo、Benigno Crespo、Alisje Churchyard、Irene García-Barbazán、Jake Baum、Marc O. Anderson、Benoît Laleu、R. Kiplin Guy

  DOI：10.1021/acs.jmedchem.0c01152

  日期：2020.10.22

  infectious diseases, causing hundreds of thousands of deaths each year, primarily in young children and pregnant mothers. Here, we report the discovery and derivatization of a series of pyrazolo[3,4-b]pyridines targeting Plasmodium falciparum, the deadliest species of the malaria parasite. Hit compounds in this series display sub-micromolar in vitro activity against the intraerythrocytic stage of the

  疟疾仍然是最致命的传染病之一，每年导致成千上万的死亡，主要是在幼儿和孕妇中。在这里，我们报道了针对恶性疟原虫（疟疾最致命的物种）的一系列吡唑并[3,4- b ]吡啶的发现和衍生化。该系列中的命中化合物在体外显示出亚微摩尔对寄生虫的红细胞内阶段具有高活性，对人成纤维细胞BJ和肝HepG2细胞系几乎没有毒性。此外，我们的命中化合物对寄生虫的肝期表现出良好的活性，但对配子体阶段的活性却很小。包括杀死率，对接率和分子动力学研究在内的寄生虫学资料表明，我们的化合物可能靶向细胞色素bc 1的Q o结合位点。
• [EN] AMIDE COMPOUNDS USEFUL IN THERAPY<br/>[FR] COMPOSÉS AMIDES UTILES EN THÉRAPIE
  申请人：PFIZER LTD

  公开号：WO2010032200A1

  公开（公告）日：2010-03-25

  A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein, R1 and R2 each independently represent H, halogen, CF3, C1-3 alkyl or C1-3 alkoxy; R3 represents C1-6 alkyl, C3-6 cycloalkyl, phenyl (optionally substituted by one or more substituents each independently selected from Ra) or Het (optionally substituted by one or more substituents each independently selected from OH, oxo, or C1-4 alkyl); R4 represents H or C1-3 alkyl; R5 represents C1-6 alkyl (optionally substituted by one or more substituents each independently selected from Rb), C3-6 cycloalkyl (optionally substituted by one or more substituents each independently selected from oxo or OH), or Het2 (optionally substituted by one or more substituents each independently selected from Rd); oxygen atom or 1 sulphur atom, or (c) 1 oxygen atom or 1 sulphur atom, (optionally substituted by one or more substituents each independently selected from OH, oxo or C1-4 alkyl); and R6 represents C1-3 alkyl (optionally substituted by one or more substituents each independently selected from Rf), C3-5 cycloalkyl (optionally substituted by one or more halogen), CN or halogen; where Rf represents halogen or phenyl: and compositions, processes for the preparation, and uses thereof, e.g. in the treatment of endometriosis or uterine fibroids.

  化合物的化学式（I），或其药学上可接受的盐或溶剂，其中，R1和R2分别独立表示H、卤素、CF3、C1-3烷基或C1-3烷氧基；R3表示C1-6烷基、C3-6环烷基、苯基（可选地由一个或多个Ra独立选择的取代基取代）或Het（可选地由一个或多个OH、氧代或C1-4烷基独立选择的取代基取代）；R4表示H或C1-3烷基；R5表示C1-6烷基（可选地由一个或多个Rb独立选择的取代基取代）、C3-6环烷基（可选地由一个或多个氧代或OH独立选择的取代基取代），或Het2（可选地由一个或多个Rd独立选择的取代基取代）；氧原子或1硫原子，或（c）1氧原子或1硫原子，（可选地由一个或多个OH、氧代或C1-4烷基独立选择的取代基取代）；和R6表示C1-3烷基（可选地由一个或多个Rf独立选择的取代基取代）、C3-5环烷基（可选地由一个或多个卤素取代）、CN或卤素；其中Rf表示卤素或苯基：以及其组合物、制备方法和用途，例如在子宫内膜异位症或子宫肌瘤的治疗中。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE COMME AGENT ANTICANCER
  申请人：PF MEDICAMENT

  公开号：WO2011045344A1

  公开（公告）日：2011-04-21

  The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.

  本发明涉及具有以下通式(I)的化合物：(公式I)以及它们的药用可接受盐、它们的制备方法及其用途，尤其是作为抗癌剂。